Maximum quantity allowed is 999
Please select the quantity
CAS RN: 857036-77-2 | Product Number: R0277
Cediranib Maleate
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- Recentin
- AZD-2171 Maleate
- 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline Maleate
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 10MG |
NT$5,120
|
22 | 0 | Contact Us | |
| 50MG |
NT$17,840
|
≥60 | 0 | Contact Us |
* The above prices include freight cost, customs, and other charges to the destination except for products that need to be shipped by sea or dry ice. For details, please contact
our distributor
in Taiwan to order our product.
* The storage conditions are subject to change without notice.
| Product Number | R0277 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__5H__2__7FN__4O__3·C__4H__4O__4 = 566.59 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive |
| CAS RN | 857036-77-2 |
| Reaxys Registry Number | 14422486 |
| MDL Number | MFCD27665457 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| NMR | confirm to structure |
Properties (reference)
GHS
Related Laws:
Transport Information:
| H.S.code* | 2933.59-000 |
Application
Cediranib Maleate: A VEGF Receptor Tyrosine Kinase Inhibitor
Receptors for VEGF (vascular endothelial growth factor-A) play a central role in vasculogenesis and angiogenesis and are therefore targets for cancer therapy. Cediranib (AZD2171) [C3918] and its water-soluble maleate are VEGF receptor tyrosine kinase inhibitors used in cancer research. (The product is for research use only.)
References
- AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
- The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies (a review)
- Cediranib , a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
- Solubility and stability of cediranib maleate
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.